Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
about
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesInhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceCeritinib: A primer for pharmacists.Targeted Lung Cancer Treatments and Eye MetastasisMass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinibGenetics of rheumatoid arthritis susceptibility, severity, and treatment response.Precision wildlife medicine: applications of the human-centred precision medicine revolution to species conservation.Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance.PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer.Liquid biopsies in lung cancer-time to implement research technologies in routine care?K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review.Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies."Scar-cinoma": viewing the fibrotic lung mesenchymal cell in the context of cancer biology.Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies.Raising the bar: the future of EGFR inhibition in non-small lung cancer.Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients.An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.Development of LC-QTOF-MS method for human lung tissue fingerprinting. A preliminary application to nonsmall cell lung cancer.Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma.Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer.Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model.An Isolated TCR αβ Restricted by HLA-A*02:01/CT37 Peptide Redirecting CD8+ T Cells To Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines.The diagnostic value of tissue button technique for specimen accusation during endobronchial ultrasound-guided transbronchial fine-needle aspiration.Targeting rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitorsConcomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer
P2860
Q28074716-E4C6155B-A52B-4DD8-9E08-F4719431D0ADQ28079309-0A8601F8-5047-4DAC-BE7A-E30A04B0CE14Q28079320-FD96A9F5-0D36-4010-B9C0-6A7A4D22745EQ30244613-68836B59-AD11-4995-B113-E7F789727162Q33566410-FE7800E6-BDFA-49CB-ADA2-9B5A2626CC19Q33778668-84FF21CE-4DEA-4D87-B8E9-F565C0C4E7F0Q33804619-2A96B882-4F42-45AD-BD27-8911E70E92D8Q33841329-24503951-6BD0-4726-B2B4-D56E7D5B2089Q36181146-2DE18808-6922-435C-8A9D-C768B61E84B0Q37060709-64CCBBCB-361E-446C-8DCD-638266A18775Q37462489-F696515C-1381-434B-A4A1-3CAECAA2F2D3Q37666880-6817EA7A-3DBB-4FF0-A0DA-5A4CC87A7E3BQ37741383-A546C237-E37A-46DD-AA12-E7CCD548A62DQ38649535-BBE0707A-2226-43F4-ACAB-FE250749E8B8Q38731776-040EC74E-474C-464C-8A65-DA768CCBB2BEQ38922208-DA69191C-22D6-4DD1-8C46-888935273F53Q38931077-87D655CD-98F2-45DF-976C-77D27D6FA143Q41340094-537B28B8-62F7-4361-A1F8-6FD86808C225Q42594342-C2E55DBD-D464-434F-9D81-F97CF18640BDQ46556584-47482478-CF3E-41F5-894B-2F71A1C47223Q47103202-8E5CB00E-3FB7-4B39-BDF4-01814A991787Q47163753-3B846AB6-001B-4DC8-A5DE-114CD612E079Q47715440-6E047F2A-3F14-4B2E-9148-A0EE9A53B447Q48179589-A39A331C-2559-4707-B59C-79F64B9A6310Q48235821-3D80B519-BCDB-4AE3-9EA1-95B283F427BDQ49887893-657ADCDB-49B0-49E4-8E90-B4E877D9A943Q50192132-6D6592D7-EAE7-444A-B334-326EF1E3B14DQ51037196-420E7D59-1282-4B05-920E-5B6374C53C40Q52628622-F163C945-659B-476F-A1C0-405E1700B81FQ52633438-C1CEF071-D6A7-485A-86B1-9BAA1B800319Q52648005-816D3D9D-51F6-4CF8-9EA3-C8363F32959EQ52745185-6620C8F5-FFF2-4CE6-BFF1-BAE5A8D0F34BQ57495887-A658660B-899D-4B3A-85D4-389E105438CCQ58552976-578BBE96-67C7-467E-B884-AD4B46E9CBDD
P2860
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Management of advanced non-sma ...... ence and treatment approaches.
@en
type
label
Management of advanced non-sma ...... ence and treatment approaches.
@en
prefLabel
Management of advanced non-sma ...... ence and treatment approaches.
@en
P2860
P356
P1476
Management of advanced non-sma ...... ence and treatment approaches.
@en
P2093
Deepa Rangachari
Meghan Shea
P2860
P304
P356
10.1177/1753465815617871
P577
2015-11-30T00:00:00Z